98 related articles for article (PubMed ID: 35048362)
1. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Li S; Dvorak CC; Lu Y; Chan D; Gobburu JVS; Long-Boyle J; Apsel Winger B
J Clin Pharmacol; 2022 Jul; 62(7):873-882. PubMed ID: 35048362
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
Wang H; Jones AK; Dvorak CC; Huang L; Orchard P; Ivaturi V; Long-Boyle J
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1603-1610. PubMed ID: 31002993
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Shah GL; Boelens JJ; Carlow D; Lin A; Schofield R; Cruz Sitner N; Alperovich A; Ruiz J; Proli A; Dahi P; Tamari R; Giralt SA; Scordo M; Admiraal R
Clin Pharmacokinet; 2022 Apr; 61(4):553-563. PubMed ID: 34859337
[TBL] [Abstract][Full Text] [Related]
4. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders.
Chandra S; Mizuno K; Zhao J; Davies SM; Marsh RA; Fukuda T; Setchell KDR; Vinks AA; Mehta PA
Br J Clin Pharmacol; 2022 Jan; 88(1):115-127. PubMed ID: 34075614
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno K; Dong M; Fukuda T; Chandra S; Mehta PA; McConnell S; Anaissie EJ; Vinks AA
Clin Pharmacokinet; 2018 May; 57(5):625-636. PubMed ID: 28918602
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
Nath CE; Shaw PJ; Montgomery K; Earl JW
Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation.
Maemura R; Wakamatsu M; Matsumoto K; Sakaguchi H; Yoshida N; Hama A; Yoshida T; Miwata S; Kitazawa H; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Suzuki K; Kawashima N; Nishikawa E; Narita A; Okuno Y; Nishio N; Kato K; Kojima S; Morita K; Muramatsu H; Takahashi Y
Cell Transplant; 2022; 31():9636897221143364. PubMed ID: 36537564
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant.
Sahasrabudhe SA; Kartha RV; Ng M; Basso LM; Mishra U; Cloyd JC; Orchard PJ; Brundage RC; Coles LD
J Clin Pharmacol; 2021 Dec; 61(12):1638-1645. PubMed ID: 34275158
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.
Langenhorst JB; Dorlo TPC; van Maarseveen EM; Nierkens S; Kuball J; Boelens JJ; van Kesteren C; Huitema ADR
Clin Pharmacokinet; 2019 May; 58(5):627-637. PubMed ID: 30327943
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation.
Brooks JT; Keizer RJ; Long-Boyle JR; Kharbanda S; Dvorak CC; Friend BD
Front Pharmacol; 2021; 12():750672. PubMed ID: 34950026
[No Abstract] [Full Text] [Related]
14. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
15. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
16. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
17. Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics.
Zhou S; Zhang R; Lv C; Lu J; Wei Y; Li C; Chen M; Li Q; Liu T
Ann Pharmacother; 2021 Apr; 55(4):440-451. PubMed ID: 32924532
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.
Nijstad AL; Nierkens S; Lindemans CA; Boelens JJ; Bierings M; Versluys AB; van der Elst KCM; Huitema ADR
Br J Clin Pharmacol; 2021 Aug; 87(8):3218-3226. PubMed ID: 33444472
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; van Tol MJ; Bartelink IH; Bredius RG; Boelens JJ; Knibbe CA
Clin Pharmacokinet; 2015 Apr; 54(4):435-46. PubMed ID: 25466602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
